Granule

Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

Retrieved on: 
Monday, February 5, 2024
Partnership, Surgeon, Kuros, Magneto, Patient, Granule, FDA, Food, Gold, Computer data storage

The Company also announced clearance to market in New Zealand for MagnetOs Granules and MagnetOs Putty.

Key Points: 
  • The Company also announced clearance to market in New Zealand for MagnetOs Granules and MagnetOs Putty.
  • Earlier in January, Kuros announced the FDA clearance of MagnetOs Easypack Putty for interbody use and MagnetOs Putty for standalone use in the posterolateral spine, meaning it can now be used without the need for autograft (patient’s own bone).
  • “We are very pleased that MagnetOs Granules has received marketing clearance for interbody use given the Granules technology is the foundation of the MagnetOs platform,” commented Chris Fair, Chief Executive Officer of Kuros Biosciences.
  • “This clearance, coupled with the MagnetOs Flex Matrix and MagnetOs Easypack Putty formulations, provides our surgeons the widest variety of advanced biologic formulations available for use in the interbody space.

Essex Bio-Technology Announces 2022 Annual Financial Results

Retrieved on: 
Wednesday, March 8, 2023
City, Traction, Conditional sentence, US FDA, COVID-19, VISTA, Clinical trial, Patent, NMPA, Acquisition, Eye, Hospital, Diabetic retinopathy, Trial of the century, CMC, European Medicines Agency, Growth, Anti-VEGF, Policy, Intellectual property, Research, Chemistry, Granule, Macular edema, Telecanthus, Patient, Invention, FDA, SkQ, Marketing, DNA, Best, Bevacizumab, D, TRIPS Agreement, Trust, Czech Republic, Ranibizumab, Therapeutic Goods Administration, Disease, Wound healing, Therapy, Cryptocurrency, Pharmaceutical industry, Property management, Vaccine, Ophthalmology, PRC, Surgery

HONG KONG, Mar 8, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2022.

Key Points: 
  • HONG KONG, Mar 8, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2022.
  • As of the date of the results announcement, the clinical operations of hospitals and outpatient clinics progressively resumed to normalcy.
  • As of 31 December 2022, the Group had cash and cash equivalents of approximately HK$544 million (2021: approximately HK$671 million).
  • Together with the interim dividend of HK$ 0.04 per ordinary share paid on 21 September 2022, the total dividend for 2022 would be HK$ 0.065 (2021: HK$ 0.095) per ordinary share.

Universe Pharmaceuticals INC Announces Inclusion of Six Products into the First Edition of Catalogue of Medicine for Patients Infected with COVID-19

Retrieved on: 
Wednesday, December 21, 2022
Universe, Radiation treatment planning, Isatis tinctoria, Sputum, Edition (book), COVID-19, Pharmacy, UPC, Catalog, Patient, Granule, Cough, Magic: The Gathering core sets, 1993–2007, INC, Hospital, The Catalogue, Tablet, Fever, Pharmaceutical industry

The included products are Banlangen Granules, Strong Loquat Extract, Pediatric Paracetamol, Vitamin C Yinqiao Tablets, Acetaminophen Tablets and Metamizole Sodium Tablets.

Key Points: 
  • The included products are Banlangen Granules, Strong Loquat Extract, Pediatric Paracetamol, Vitamin C Yinqiao Tablets, Acetaminophen Tablets and Metamizole Sodium Tablets.
  • The Catalogue supplements the list of recommended medicine in the Ninth Edition of the National Diagnosis and Treatment Plan.
  • Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC, commented, “We are pleased to have our products included in the Catalogue.
  • Currently, the order volume of our three products, Banlangen Granules, Strong Loquat Extract and Pediatric Paracetamol, continues to increase.

Essex Bio-Technology Announces 2021 Financial Results

Retrieved on: 
Tuesday, March 22, 2022
Conditional sentence, Hospital, SkQ, NMPA, US, Exudate, VISTA, Therapeutic Goods Administration, Trust, Trial of the century, Association of British HealthTech Industries, Cornea, Science, The Group, Therapy, DNA, Patent, Investment, Growth, Clinical trial, European Medicines Agency, Board, Board on Science, Technology, and Economic Policy, Review, Duane syndrome, COVID, Patient, IP, Company, Growth factor, Leadership, Group, Granule, City, US FDA, Oxidative stress, Czech Republic, MAH, COVID-19, Traction, Bevacizumab, Acquisition, Property management, Vaccine, Pharmaceutical industry, Television, Animal, Cosmetics, Renewable energy, Surgery, Dermatology, PRC, Ophthalmology

HONG KONG, Mar 22, 2022 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021.

Key Points: 
  • HONG KONG, Mar 22, 2022 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021.
  • Essex achieved significant progression and encouraging performances amid the COVID-19 pandemic and macro uncertainties.
  • Mr. Patrick Ngiam, Chairman of Essex, said, "2021 has been a year full of diverse challenges.
  • The Group has achieved significantly improved financial performances in the financial year ended 31 December 2021.

Gold&Green Foods® Named to Fast Company's Annual List of the World's Most Innovative Companies for 2022

Retrieved on: 
Wednesday, March 9, 2022
Granule, Organic acid, Fast Company, Oat, Gold, Map, Food, Culture, World, Meat, Editorial, Organization, Flour, Agriculture, Nordic

HELSINKI, March 9, 2022 /PRNewswire/ -- Gold&Green Foods has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies for 2022, ranking #7 in the Food Sector .

Key Points: 
  • HELSINKI, March 9, 2022 /PRNewswire/ -- Gold&Green Foods has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies for 2022, ranking #7 in the Food Sector .
  • In addition to the World's 50 Most Innovative Companies, 528 organizations are recognized across 52 categories.
  • "We are truly honored to be recognized among such distinguished companies in Fast Company's list of the World's Most Innovative Companies," said Annette Kauppinen, Chief Marketing Officer of Gold&Green Foods.
  • To see the full list of World's Most Innovative Companies for 2022, click here .

Shineway (2877.HK) Q1 revenue increased by 37.0%

Retrieved on: 
Thursday, May 13, 2021
Granule

b"HONG KONG, May 13, 2021 - (ACN Newswire) - China Shineway Pharmaceutical Group Limited (2877.HK) recently released its unaudited turnover for the three months ended 31 March 2021 (Q1 2021) based on its management accounts.\nRevenue for Q1 2021 went up 37.0% YoY, which implies a growth of 20.4% over the pre-COVID 19 levels, as compared with the same period of 2019.

Key Points: 
  • b"HONG KONG, May 13, 2021 - (ACN Newswire) - China Shineway Pharmaceutical Group Limited (2877.HK) recently released its unaudited turnover for the three months ended 31 March 2021 (Q1 2021) based on its management accounts.\nRevenue for Q1 2021 went up 37.0% YoY, which implies a growth of 20.4% over the pre-COVID 19 levels, as compared with the same period of 2019.
  • The Group's main product types all achieved significant growth.
  • Sales of injection products went up by 34.2%; soft capsule products recorded growth of 6.6%; granule products showcased the strongest turnover growth of 62.2%; turnover of TCM formula granule products increased by 50.5%.
  • For products in other forms, turnover grew by 54.2%.\nCopyright 2021 ACN Newswire .

Expert Seminar on Anti-COVID-19 Chinese Herbal Medicine “Honee Taishen Granule” Held in Ritan, Beijing

Retrieved on: 
Monday, December 7, 2020
Infectious diseases, Alternative medicine, Health, Granule, System Global Area, Beijing, Geography of Asia

On November 26, 2020, Beijing Handian Pharmaceutical held an expert seminar on anti-COVID-19 medicine Honee Taishen Granule in Ritan, Beijing.

Key Points: 
  • On November 26, 2020, Beijing Handian Pharmaceutical held an expert seminar on anti-COVID-19 medicine Honee Taishen Granule in Ritan, Beijing.
  • View the full release here: https://www.businesswire.com/news/home/20201206005083/en/
    Expert Seminar on anti-COVID-19 Chinese herbal medicine Honee Taishen Granule held in Ritan, Beijing (Photo: Business Wire)
    At this meeting, the company invited a number of experts from the Chinese Academy of Sciences and the Chinese Academy of Medical Sciences to discuss the current research results of "Taishen Granules" and put forward their suggestions on the future research and development direction of this drug.
  • The company started a long-term anti-plague research program since Ebola outbreak in 2015, and Taishen Granule comes from a reserve formula of that program.
  • The Taishen Granule expert seminar is held here in the hope that Taishen Granule will act like the sun to dispel the pain and darkness brought by COVID-19 to this world.

Industry Players in Potato Flakes Market Capitalize on Ready-to-eat Food Trends, Leveraging State-of-the Art Drum Dryers: TMR

Retrieved on: 
Wednesday, December 2, 2020
Plants, Plant morphology, Branches of biology, Cuisine of Northern Ireland, Irish cuisine, Potato, Solanum, Tubers, Marketplace, Granule

According to a latest study by Transparency Market Research, the market will witness the impact of the unprecedented COVID-19 outbreak.

Key Points: 
  • According to a latest study by Transparency Market Research, the market will witness the impact of the unprecedented COVID-19 outbreak.
  • These companies are therefore focusing on mitigating challenges hindering the smooth supply operations, while leveraging their online presence.
  • Potato Granules Market - The fast-paced sedentary lifestyles have greatly influenced and altered the eating patterns and habits of the consumers.
  • Furthermore, the ever-increasing food processing industry and growing market prospects for foodservice providers, is again contributing to the growing demand for potato granules.

Shineway Pharmaceutical (2877.HK) recorded 29.4% revenue growth for October 2020

Retrieved on: 
Monday, November 30, 2020
Pharmacology, Health sciences, Pharmaceutical industry, Pharmaceutical sciences, Dosage forms, Pharmacokinetics, Granule, Capsule

HONG KONG, Nov 30, 2020 - (ACN Newswire) - Shineway Pharmaceutical (stock code: 2877.HK) recorded 29.4% revenue growth for October 2020 in comparison with the same period last year, as sales of injection products, soft capsule products, granule products, TCM formula granules, and other dosage forms went up 38.9%, 17.4%, 38.1%, 7.9% and 54.0% respectively.

Key Points: 
  • HONG KONG, Nov 30, 2020 - (ACN Newswire) - Shineway Pharmaceutical (stock code: 2877.HK) recorded 29.4% revenue growth for October 2020 in comparison with the same period last year, as sales of injection products, soft capsule products, granule products, TCM formula granules, and other dosage forms went up 38.9%, 17.4%, 38.1%, 7.9% and 54.0% respectively.
  • Copyright 2020 ACN Newswire .
  • All rights reserved.

Farlong Pharmaceutical Offers Intelligent TCM Granules Dispensing System and Drop Ship Service For Licensed Practitioners

Retrieved on: 
Monday, October 5, 2020
Health, Pharmacy, Articles, Alternative medicine, Pseudoscience, Traditional Chinese medicine, Traditional medicine, Granule, Dispensary

WALNUT, Calif., Oct. 5, 2020 /PRNewswire-PRWeb/ -- Farlong Pharmaceutical , a vertically integrated, plant-based ingredient and supplement company, is offering the first and only Intelligent TCM (traditional Chinese medicine) Granules Dispensing System and drop-ship service in the U.S.

Key Points: 
  • WALNUT, Calif., Oct. 5, 2020 /PRNewswire-PRWeb/ -- Farlong Pharmaceutical , a vertically integrated, plant-based ingredient and supplement company, is offering the first and only Intelligent TCM (traditional Chinese medicine) Granules Dispensing System and drop-ship service in the U.S.
  • This automated service takes the responsibility off of practitioners, allowing them to spend their time seeing more patients.
  • Farlong partners with practitioner offices to operate its Intelligent Dispensing System, offering the highest level of safety with a built-in error checking and visual and audio verification system, ensuring the right herbs are dispensed and eliminating human error.
  • "Now more than ever, our one of a kind auto herb granule dispensary system is proving beneficial to both practitioners and patients," Jing Struve, CEO and executive director of Farlong Pharmaceutical.